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For investigative cutaneous biologists a link between in-
flammation and skin cancer is a topic frequently discussed
when multi-stage chemical carcinogenesis and photo-
carcinogenesis models are presented. Indeed, the inflam-
matory process includes the release of cytokines, growth
factors, chemotactic polypeptides, and prostaglandins,
which have become favorite targets for prevention of chem-
ical induced as well as UV-light-induced skin cancer (Marks
and Furstenberger, 2000; Tripp et al, 2003; Wilgus et al,
2003; Bowden, 2004). Dissecting the mediators of inflam-
mation in cutaneous carcinogenic pathways has revealed
key roles for prostaglandins, cyclooxygenase-2, tumor ne-
crosis factor-a (TNF-a), AP-1, nuclear factor-kB (NF-kB),
signal transducer and activator of transcription (STAT)3, and
others (Buckman et al, 1998; Moore et al, 1999; Suganuma
et al, 1999; Young et al, 1999; Chan et al, 2004; Lind et al,
2004). Besides these experimental results, several clinical
conditions associated with inflammation appear to predis-
pose the patient to increased susceptibility for skin cancer
including discoid lupus erythematosus, dystrophic epider-
molysis bullosa, and chronic wound sites. Despite this vast
collection of data and clinical observations, however, there
are several dermatological settings in which chronic, and
even lifelong, skin diseases associated with inflammation
do not predispose to conversion of lesions into malignan-
cies such as psoriasis, atopic dermatitis, and Darier’s
disease.
The purpose of this commentary is to summarize a rap-
idly accumulating body of evidence providing new molec-
ular insights linking inflammation with the promotion of
tumorigenesis, and to remind the reader that such a link
may not be as simple as currently portrayed because cer-
tain types of inflammatory processes in skin (and possibly
other tissues as well) may also serve a tumor suppressor
function. Here we focus on such a dualistic viewpoint, and
offer a new perspective on potential molecular mechanisms
that regulate the pro-oncogenic, as well as the tumor sup-
pressor, effects of chronic inflammation, and tumor devel-
opment using psoriasis as our primary disease model.
Over the past few months, several publications in leading
biomedical journals grappled with an important issue in
oncology, namely, defining potential links between chronic
tissue damage, inflammation, and the development of can-
cer (Beachy et al, 2004; Bhowmick et al, 2004; Greten et al,
2004; Pikarsky et al, 2004). In an essay concept entitled
‘‘Mending and Malignancy,’’ Beachy et al (2004) point out
the clinical link between persistent heartburn and adeno-
carcinoma of the esophagus. They focus on injured epithe-
lium and highlight molecular pathways contributing to an
expanded stem cell pool that, together with mutagenic
agents, contribute to carcinogenesis. They conclude that
understanding the response to epithelial injury may lead to
useful strategies for cancer prevention and therapy. In ad-
dition, Balkwill and Coussens (2004) reviewed the role of the
NF-kB signal transduction pathway that can regulate in-
flammation and also promote malignancy. Their review
summarized the latest findings revealed in a letter to Nature
by Pikarsky et al (2004). Using Mdr2 knockout mice in which
hepatitis is followed by hepatocellular carcinoma (HCC),
Pikarsky et al implicated TNF-a upregulation in tumor pro-
motion of HCC, and suggest that TNF-a and NF-kB are
potential targets for cancer prevention in the context of
chronic inflammation. A similar conclusion was reached
with respect to NF-kB by an independent group of inves-
tigators using a model of experimental dextran sodium sul-
fate-induced colitis, in which inactivation of the IkB kinase
resulted in reduced colorectal tumors (Greten et al, 2004).
Way before the molecular clues for cancer had been inves-
tigated, Hawkins (1835) made the clinical observation that
squamous cell carcinoma can be a long-term sequela of
chronic osteomyelitis in the overlying skin. Furthermore, it
has been argued that the immune response contributes
significantly to fostering a tumorigenic process through
CD4þ T cells, or other inflammatory links (Daniel et al,
2003; Vakkila and Lotze, 2004).
Although there are many other clinical conditions sup-
porting the concept that inflammation is a critical com-
ponent of tumor progression (e.g., reflux esophagitis/
esophageal cancer; inflammatory bowel disease/colorectal
cancer) (Coussens and Werb, 2002), there is at least one
notable example that does not fit this paradigm. As de-
scribed below, psoriasis is a chronic cutaneous inflamma-
tory disease, which is seldom if ever accompanied by
cancer, suggesting the relationship between tissue repair,
inflammation, and development of cancer may not be as
simple as portrayed by the aforementioned reviews and
experimental results. Besides psoriasis, other noteworthy
observations pointing to more complexity include the ob-
servation that in the Mdr2 knockout mice, we rarely detect
bile duct tumors despite extensive inflammation, NF-kB
activation, and abundant proliferation of bile ducts in portal
spaces (Pikarsky et al, 2004). Moreover, in a skin cancer
mouse model, NF-kB was shown to inhibit tumor formation
(Dajee et al, 2003). Thus, the composition of inflammatory
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mediators, or the properties of the responding epithelial
cells (e.g. signaling machinery, metabolic status), may
dictate either tumor promotion or tumor suppression, as
summarized in Fig 1.
As highlighted in Fig 1, we suggest that chronic inflam-
mation and tissue repair can trigger pro-oncogenic events,
but also that tumor suppressor pathways may be upregu-
lated at various sites of injury and chronic cytokine net-
working. The principal support for such a dualistic viewpoint
is based on both clinical and biochemical characteristics of
psoriatic plaques.
Psoriatic plaques represent a common tissue response
to injury in genetically predisposed individuals (approxi-
mately 2%–3% of the population worldwide) with prominent
and persistent inflammation that does not lead to cancer
development (Nickoloff, 2001). Moreover, conversion from
clinically symptomless skin to thick, erythematous scaling
plaques includes a remodeling of both epidermal and der-
mal compartments with neovascularization accompanied
by activation of CD4þ T cells and other immunocytes
(Nickoloff and Nestle, 2004). The psoriatic plaque is further
interrogated because STAT3 signaling, which is important in
cutaneous carcinogenesis, is also dramatically increased in
lesional keratinocytes (Chan et al, 2004; Sano et al, 2005).
This remarkable set of cellular changes is entirely reversible,
particularly when agents that neutralize TNF-a are admin-
istered to patients with psoriasis (Nickoloff and Nestle,
2004). Perhaps of greatest interest to this topic is that le-
sional keratinocytes are characterized by a high resistance
to apoptosis, and yet only rarely, if ever, become converted
to carcinomas (Wrone-Smith et al, 1997; Nickoloff, 2001).
NF-kB has also been implicated in psoriatic lesions, as
agents targeting this signal transduction pathway have
shown pre-clinical efficacy (Zollner et al, 2002). Further-
more, in this issue, Lizzul et al (2005) demonstrate NF-kB
signaling is activated in psoriatic plaques and is down-
regulated following administration of a TNF-a targeting
agent (e.g., etanercept).
TNF-a signaling is of particular relevance to this topic of
inflammation and skin cancer. On the one hand, psoriatic
plaques are dependent on TNF-a signaling, as agents that
block TNF-a are highly effective in treating psoriatic patients
(Nickoloff and Nestle, 2004). TNF-a also appears to be es-
sential for skin carcinogenesis, however, as mice genetically
engineered to be deficient in TNF-a are resistant to skin
carcinogenesis (Moore et al, 1999). Furthermore, TNF-a re-
ceptor 1-mediated signaling is required for skin cancer de-
velopment in mice when accompanied by NF-kB inhibition
(Lind et al, 2004). Thus, the interplay between inflammatory
cytokines such as TNF-a and the NF-kB signaling pathway
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Proposed dualistic viewpoint for
role of inflammation in both of
the complex processes culminating
in either tumor promotion (left-side
panel) and tumor suppression (right-
side panel). Note following a stimulus
which leads to tissue damage and
chronic inflammation in the skin, two
possible pathways are envisioned that
may involve the participation of kera-
tinocytes, epidermal stem cells, and
dermal stromal cells participating in
signaling pathways including the fol-
lowing for tumor promotion (ROS, DNA
damage, PGE2/COX-2, AP-1, TNF-a,
STAT3, NF-kB) and tumor suppression
(TGFb, defensins-infectious agents,
p21WAF1, NF-kB). Many questions re-
main to be answered in defining the
precise mechanistic role for these me-
diators and signal transducers in de-
termining whether skin cancer or
senescence is the final biological path-
way resulting from chronic cutaneous
inflammation. ROS, reactive oxygen
species; COX-2, cyclooxygenase-2;
TNF-a, tumor necrosis factor-a; STAT,
signal transducer and activator of tran-
scription; NF-kB, nuclear factor-kB;
TGFb, transforming growth factor b.
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must be taken into consideration when attempting to link
inflammation and skin cancer (Pasparakis et al, 2002).
One cannot easily dismiss the many dilemmas raised by
the psoriatic plaque that confound a simple link between
tissue repair, inflammation, and carcinogenesis. Since it is
easily visible to the naked eye, and patients may suffer from
such lesions for decades, it is difficult to argue that various
skin cancers such as squamous cell carcinoma, basal cell
carcinoma, or melanoma actually do develop within plaques
but are being overlooked by patients and dermatologists
(Nickoloff, 2004). Remarkably, psoriatic plaques are inten-
tionally exposed to mutagenic agents including excessive
sunlight, topical administration of crude coal tar, or paren-
teral DNA cross-linking agent-psoralen followed by ultravi-
olet light (i.e. PUVA). Moreover, these treatments are known
to induce skin cancer in non-lesional skin (Nijsten and Stern,
2003). To add insult to injury, prior to the use of new and
effective biological agents selectively targeting TNF-a, thou-
sands, if not tens of thousands, of patients were and are
being treated with immunosuppressive agents such as cor-
ticosteroids, or cyclosporine A. Thus, since psoriatic skin is
characterized by altered differentiation, angiogenesis, in-
creased telomerase activity, proliferative changes, and
apoptosis resistance (McKenzie and Sabin, 2003), one
would expect that each and every psoriatic plaque would
be converted to cancer, or at least serve as fertile soil for the
presence of non-epithelial skin cancers over time (Nickoloff,
2001, 2004).
How can one reconcile the key characteristics of psoria-
tic lesions with the paucity of cancers that arise within such
plaques? There is a biological context requiring consider-
ation in which cells can simultaneously resist apoptosis
and transformation—namely the senescent state (Campisi,
2001). Using normal keratinocytes in culture and exposing
these cells to cytokines that are present in psoriatic plaques
such as TNF-a or interferon-g, the keratinocytes become
irreversibly growth arrested and acquire a resistance to
apoptosis (Chaturvedi et al, 1999, 2003). Many biochemical
features are present in keratinocytes undergoing accelerat-
ed senescence including induction of senescence-associ-
ated b-galactosidase and cyclin-dependent kinase
inhibitors such as members of the INK4a/Arf locus (p12,
p14ARF, p16) as well as p21WAF1 (Healy et al, 1995). Several
senescence markers can also be found within psoriatic
plaques in vivo (Chaturvedi et al, 2003; Elias et al, 2004;
Nickoloff, 2004).
Thus, we postulate that chronic inflammation in psoriatic
skin induces a state of ‘‘tumor demotion’’ possibly through
triggering premature, or accelerated, cell senescence.
There may also be paracrine effects emanating from lesion-
al keratinocytes or underlying fibroblasts that could effec-
tively suppress neighboring non-epithelial cells, such as
melanoma cells, as well. Secreted proteins over-produced
by senescent keratinocytes potentially mediating an anti-
tumorigenic response include maspin and transforming
growth factor b (TGFb) isoforms (Tremain et al, 2000; Nick-
oloff et al, 2004). As regards TGFb, Bhowmick et al (2004)
described the phenotype of Tgfbr2fspKO mice in which
TGFb receptor type II is selectively inactivated in fibroblasts,
resulting in intraepithelial neoplasia in prostate and invasive
squamous cell carcinoma of the forestomach. In addition,
Becker et al (2004) reported that TGFb suppresses colon
cancer progression in an injury/inflammation model via in-
hibition of interleukin-6 trans signaling. Thus, a keratinocyte
senescence program culminating in TGFb may, through au-
tocrine and paracrine mechanism, play a major role in sup-
pressing tumorigenesis at or around the psoriatic plaque
(Campisi, 2001). Perhaps the presence of senescent kera-
tinocytes restricts expansion of transformed stem cells from
small clones to large clones, which could account for the
lack of tumorigenesis (Hennings et al, 1990); or the clonal
expansion of keratinocytes in psoriatic plaques does not
include a stem cell component (Chaturvedi et al, 2002). It
should also be noted that in the case of psoriasis, epide-
miological data on cancer incidence indicate there is no
general skin protection as revealed by PUVA-induced le-
sions that occur on non-plaque containing skin (Nijsten and
Stern, 2003). Thus, whatever the mechanism by which
plaques resist transformation, it must be confined to the
lesional skin itself, and not necessarily protect surrounding
skin or create a more generalized field effect.
An alternative consideration mediating tumor suppres-
sion within psoriatic plaques is that the inflammatory infil-
trate generates anti-infectious factors such as b-defensins
(Harder et al, 1997), which compensates for barrier disrup-
tion by inhibiting invasion of various pathogenic organisms
such as bacterial, fungal, and viral infections (Henseler and
Christophers, 1995). The presence of such factors that
sterilize lesions could serve to target and suppress poten-
tially transforming infectious agents. In addition, factors like
b-defensins may serve to bridge innate and adaptive im-
mune responses, thereby combating neoplastic cells as
they initially appear (Ganz, 2003).
Interactions between epithelial cells and microflora are
gaining increasing attention in the gastrointestinal tract as
resident commensal bacteria may activate cell survival sig-
nals via Toll-like receptors and enhanced NF-kB signaling
(Clevers, 2004; Rakoff-Nahoum et al, 2004). The role of NF-
kB signaling within keratinocytes may serve as a tumor
suppressor by inducing growth arrest via p21WAF (Zhang
et al, 2004), or as a tumor promoter by enhancing their sur-
vival and resistance to apoptosis. Thus, just as we have
come to appreciate that AP-1 and Notch signaling may be
double-edged swords when it comes to tumor promotion
versus tumor suppression, so too may inflammatory reac-
tions that activate such signaling pathways have dualistic,
and perhaps even directly opposing influences depending
on the cellular context, strength and persistence of signals,
and other microenvironmental factors (Eferl and Wagner,
2003; Radtke and Raj, 2003).1
As suggested by Radisky et al (2001), anti-cancer re-
search might be more effective if aimed at eradicating the
cause or signaling context of abnormality, rather than just
treating the end result. Devoting efforts at unraveling the
signaling pathways and cellular context of keratinocytes
within psoriatic plaques could provide novel insights into
potent tumor suppressive pathways that lie within a chro-
nic inflammatory network. It is likely that all inflammatory
conditions are not alike, whether afflicting the skin or
1Nickoloff BJ, et al: JID—Montagna Symposium, 2004, sub-
mitted.
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extra-cutaneous sites, and we need to distinguish between
those chronic inflammatory sites that predispose to cancer
development, and those that may prevent tumor formation.
In any event, exploring and discovering the essential el-
ements mediating inflammation-induced tumor suppression
may pay dividends beyond the heartbreak of psoriasis in
skin to many other organ systems such as the liver, respi-
ratory, and gastrointestinal tracts, in which the response to
tissue injury is repair and chronic inflammation. In conclu-
sion, it would seem prudent to remember the paradigm
proposed by Weiss (1971) in which he suggested that pre-
malignant cells do not comprise an isolated island, but are
rather a focus of intense tissue interactions. The myriad in-
flammatory effects of the tumor microenvironment are im-
portant for understanding tumor development, as well as
tumor suppression and senescence, and for the design of
efficacious prevention strategies against inflammation-as-
sociated cancer.
This work was supported by NIH Grant AR 40065, AR 47814 (B. J. N.)
and Prostate Cancer Foundation Israel-Center of Excellence (E. P. and
Y. B. N.). The authors thank Drs J. Robinson, F. Bennett, J. Krueger, K.
Gordon, B. Bonish, J. DiGiovanni, M. Denning, and L. Miele for helpful
suggestions.
DOI: 10.1111/j.0022-202X.2005.23724.x
References
Balkwill F, Coussens LM: Cancer: An inflammatory link. Nature 431:405–406,
2004
Beachy PA, Karhadkar SS, Berman DM: Mending and malignancy. Nature
431:402, 2004
Becker C, Fantini MC, Schramm C, et al: TGF-beta suppresses tumor progres-
sion in colon cancer by inhibition of IL-6 trans-signaling. Immunity
21:491–501, 2004
Bhowmick NA, Chytil A, Plieth D, et al: TGF-beta signaling in fibroblasts mod-
ulates the oncogenic potential of adjacent epithelia. Science 303:
848–851, 2004
Bowden GT: Prevention of non-melanoma skin cancer by targeting ultraviolet-B-
light signalling. Nat Rev Cancer 4:23–35, 2004
Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, Pentland AP:
COX-2 expression is induced by UVB exposure in human skin: Implica-
tions for the development of skin cancer. Carcinogenesis 19:723–729,
1998
Campisi J: Cellular senescence as a tumor-suppressor mechanism. Trends Cell
Biol 11:S27–S31, 2001
Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, DiGiovanni J:
Disruption of Stat3 reveals a critical role in both the initiation and the
promotion stages of epithelial carcinogenesis. J Clin Invest 114:720–728,
2004
Chaturvedi V, Cesnjaj M, Bacon P, Panella J, Choubey D, Diaz MO, Nickoloff BJ:
Role of INK4a/Arf locus-encoded senescent checkpoints activated in
normal and psoriatic keratinocytes. Am J Pathol 162:161–170, 2003
Chaturvedi V, Chu MS, Carrol BM, Brenner BSJW, Nickoloff BJ: Estimation of size
of clonal unit for keratinocytes in normal human skin. Arch Pathol Lab
Med 126:420–424, 2002
Chaturvedi V, Qin JZ, Denning MF, Choubey D, Diaz MO, Nickoloff BJ: Apoptosis
in proliferating, senescent, and immortalized keratinocytes. J Biol Chem
274:23358–23367, 1999
Clevers H: At the crossroads of inflammation and cancer. Cell 118:671–674, 2004
Coussens LM, Werb Z: Inflammation and cancer. Nature 420:860–867, 2002
Dajee M, Lazarov M, Zhang JY, et al: NF-kappaB blockade and oncogenic Ras
trigger invasive human epidermal neoplasia. Nature 421:639–643, 2003
Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D:
Immune enhancement of skin carcinogenesis by CD4þ T cells. J Exp
Med 197:1017–1028, 2003
Eferl R, Wagner EF: AP-1: A double-edged sword in tumorigenesis. Nat Rev
Cancer 3:859–868, 2003
Elias AN, Barr RJ, Nanda VS: p16 expression in psoriatic lesions following ther-
apy with propylthiouracil, an antithyroid thioureylene. Int J Dermatol
43:889–892, 2004
Ganz T: Defensins: Antimicrobial peptides of innate immunity. Nat Rev Immunol
3:710–720, 2003
Greten FR, Eckmann L, Greten TF, et al: IKKbeta links inflammation and tumori-
genesis in a mouse model of colitis-associated cancer. Cell 118:285–296,
2004
Harder J, Bartels J, Christophers E, Schroder JM: A peptide antibiotic from hu-
man skin. Nature 387:861, 1997
Hawkins C: Cases of warty tumors in cicatrices. Med Chir Trans 19:19, 1835
Healy E, Reynolds NJ, Smith MD, Harrison D, Doherty E, Campbell C, Rees JL:
Up-regulation of p21WAF1/CIP1 in psoriasis and after the application of
irritants and tape stripping. J Invest Dermatol 105:274–279, 1995
Hennings H, Robinson VA, Michael DM, Pettit GR, Jung R, Yuspa SH: Devel-
opment of an in vitro analogue of initiated mouse epidermis to study
tumor promoters and antipromoters. Cancer Res 50:4794–4800, 1990
Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad De-
rmatol 32:982–986, 1995
Lind MH, Rozell B, Wallin RP, van Hogerlinden M, Ljunggren HG, Toftgard R, Sur I:
Tumor necrosis factor receptor 1-mediated signaling is required for skin
cancer development induced by NF-kappaB inhibition. Proc Natl Acad
Sci USA 101:4972–4977, 2004
Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, Gottlieb AB:
Differential expression of phosphorylated NF-kB in normal and psoriatic
epidermis and down regulation of NF-kB in response to treatment with
etanercept. J Invest Dermatol 124:1275–1283, 2005
Marks F, Furstenberger G: Cancer chemoprevention through interruption of mul-
tistage carcinogenesis. The lessons learnt by comparing mouse skin
carcinogenesis and human large bowel cancer. Eur J Cancer 36:314–329,
2000
McKenzie RC, Sabin E: Aberrant signalling and transcription factor activation
as an explanation for the defective growth control and differentiation
of keratinocytes in psoriasis: A hypothesis. Exp Dermatol 12:337–345,
2003
Moore RJ, Owens DM, Stamp G, et al: Mice deficient in tumor necrosis factor-
alpha are resistant to skin carcinogenesis. Nat Med 5:828–831, 1999
Nickoloff BJ: Creation of psoriatic plaques: The ultimate tumor suppressor path-
way. A new model for an ancient T-cell-mediated skin disease. Viewpoint.
J Cutan Pathol 28:57–64, 2001
Nickoloff BJ: The skin cancer paradox of psoriasis: A matter of life and death
decisions in the epidermis. Arch Dermatol 140:873–875, 2004
Nickoloff BJ, Lingen MW, Chang BD, et al: Tumor suppressor maspin is up-
regulated during keratinocyte senescence, exerting a paracrine anti-
angiogenic activity. Cancer Res 64:2956–2961, 2004
Nickoloff BJ, Nestle FO: Recent insights into the immunopathogenesis of pso-
riasis provide new therapeutic opportunities. J Clin Invest 113:1664–1675,
2004
Nijsten TE, Stern RS: The increased risk of skin cancer is persistent after dis-
continuation of psoralenþultraviolet A: A cohort study. J Invest Dermatol
121:252–258, 2003
Pasparakis M, Courtois G, Hafner M, et al: TNF-mediated inflammatory skin
disease in mice with epidermis-specific deletion of IKK2. Nature 417:
861–866, 2002
Pikarsky E, Porat RM, Stein I, et al: NF-kappaB functions as a tumour promoter in
inflammation-associated cancer. Nature 431:461–466, 2004
Radisky D, Hagios C, Bissell MJ: Tumors are unique organs defined by abnormal
signaling and context. Semin Cancer Biol 11:87–95, 2001
Radtke F, Raj K: The role of notch in tumorigenesis: Oncogene or tumour sup-
pressor? Nat Rev Cancer 3:756–767, 2003
Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R: Rec-
ognition of commensal microflora by toll-like receptors is required for
intestinal homeostasis. Cell 118:229–241, 2004
Sano S, Chan KS, Carbajal S, et al: Stat3 links activated keratinocytes and
immunocytes required for development of psoriasis in a novel transgenic
mouse model. Nat Med 11:43–49, 2005
Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H: Essential role of
tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed
by TNF-alpha-deficient mice. Cancer Res 59:4516–4518, 1999
Tremain R, Marko M, Kinnimulki V, Ueno H, Bottinger E, Glick A: Defects in TGF-
beta signaling overcome senescence of mouse keratinocytes expressing
v-Ha-ras. Oncogene 19:1698–1709, 2000
Tripp CS, Blomme EA, Chinn KS, Hardy MM, LaCelle P, Pentland AP: Epidermal
COX-2 induction following ultraviolet irradiation: Suggested mechanism
for the role of COX-2 inhibition in photoprotection. J Invest Dermatol
121:853–861, 2003
INFLAMMATION AND CANCER xiii124 : 6 JUNE 2005
Vakkila J, Lotze MT: Inflammation and necrosis promote tumour growth. Nat Rev
Immunol 4:641–648, 2004
Weiss PA: A cell is not an island entire of itself. Perspect Biol Med 14:182–205,
1971
Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM: Inhibi-
tion of cutaneous ultraviolet light B-mediated inflammation and tumor
formation with topical celecoxib treatment. Mol Carcinogen 38:49–58,
2003
Wrone-Smith T, Mitra RS, Thompson CB, Jasty R, Castle VP, Nickoloff BJ: Ker-
atinocytes derived from psoriatic plaques are resistant to apoptosis
compared with normal skin. Am J Pathol 151:1321–1329, 1997
Young MR, Li JJ, Rincon M, Flavell RA, Sathyanarayana BK, Hunziker R, Colburn
N: Transgenic mice demonstrate AP-1 (activator protein-1) transactivation
is required for tumor promotion. Proc Natl Acad Sci USA 96:9827–9832,
1999
Zhang JY, Green CL, Tao S, Khavari PA: NF-kappaB RelA opposes epidermal
proliferation driven by TNFR1 and JNK. Genes Dev 18:17–22, 2004
Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH: Protea-
some inhibition reduces superantigen-mediated T cell activation and the
severity of psoriasis in a SCID-hu model. J Clin Invest 109:671–679,
2002
xiv NICKOLOFF ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
